Literature DB >> 21207164

Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.

Luiz Felipe de Campos-Lobato1, Luca Stocchi, Andre da Luz Moreira, Daniel Geisler, David W Dietz, Ian C Lavery, Victor W Fazio, Matthew F Kalady.   

Abstract

BACKGROUND: The aim of this study was to evaluate the clinical implications of pathologic complete response (pCR) (i.e., T0N0M0) after neoadjuvant chemoradiation and radical surgery in patients with locally advanced rectal cancer.
MATERIALS AND METHODS: A single-center, prospectively maintained colorectal cancer database was queried for patients with primary cII and cIII rectal cancer staged by CT and ERUS/MRI undergoing long-course neoadjuvant chemoradiation followed by proctectomy with curative intent between 1997 and 2007. Patients were stratified into pCR and no-pCR groups and compared with respect to demographics, tumor and treatment characteristics, and oncologic outcomes. Outcomes evaluated were 5-year overall survival, disease-free survival, disease-specific mortality, local recurrence, and distant recurrence.
RESULTS: The query returned 238 patients (73% male), with a median age of 57 years and median follow-up of 54 months. Of these, 58 patients achieved pCR. Patients with pCR vs no-pCR were statistically comparable with respect to demographics, chemoradiation regimens, tumor distance from anal verge, clinical stage, surgical procedures performed, and follow-up time. No patient with pCR had local recurrence. Overall survival and distant recurrence were also significantly improved for patients achieving pCR.
CONCLUSIONS: Achievement of pCR after neoadjuvant chemoradiation is associated with greatly improved cancer outcomes in locally advanced rectal cancer. Future studies should evaluate the relationship between increases in pCR rates and improvements in cancer outcomes in this population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207164     DOI: 10.1245/s10434-010-1506-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  59 in total

Review 1.  Current evidence regarding the role of adjuvant chemotherapy in rectal cancer patients with pathologic complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.

Authors:  Ioannis Baloyiannis; Konstantinos Perivoliotis; Styliani Vederaki; Georgios Koukoulis; Dimitrios Symeonidis; George Tzovaras
Journal:  Int J Colorectal Dis       Date:  2021-03-27       Impact factor: 2.571

2.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila
Journal:  Lancet Oncol       Date:  2015-07-14       Impact factor: 41.316

3.  Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation.

Authors:  Oliver S Chow; Sujata Patil; Metin Keskin; J Joshua Smith; Maria Widmar; David D Smith; Karin Avila; Jinru Shia; Peiguo Chu; Julio Garcia-Aguilar
Journal:  J Gastrointest Surg       Date:  2019-02-04       Impact factor: 3.452

4.  A single institution's long-term follow-up of patients with pathological complete response in locally advanced rectal adenocarcinoma following neoadjuvant chemoradiotherapy.

Authors:  Franscois Runau; Anna Collins; Glenn Ace Fenech; Eleanor Ford; Nikoletta Dimitriou; Sanjay Chaudhri; Justin M C Yeung
Journal:  Int J Colorectal Dis       Date:  2016-11-24       Impact factor: 2.571

5.  One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer.

Authors:  M A Pereira; A R Dias; S F Faraj; C S R Nahas; A R Imperiale; C F S Marques; G C Cotti; B C Azevedo; S C Nahas; E S de Mello; U Ribeiro
Journal:  Tech Coloproctol       Date:  2017-08-17       Impact factor: 3.781

6.  Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.

Authors:  J Joshua Smith; Isaac Wasserman; Sarah A Milgrom; Oliver S Chow; Chin-Tung Chen; Sujata Patil; Karyn A Goodman; Julio Garcia-Aguilar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-18       Impact factor: 7.038

7.  Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer.

Authors:  Cihan Gani; Ulrich Grosse; Stephan Clasen; Andreas Kirschniak; Martin Goetz; Claus Rödel; Daniel Zips
Journal:  Strahlenther Onkol       Date:  2018-07-09       Impact factor: 3.621

8.  Clinical Significance of the Endoscopic Finding in Predicting Complete Tumor Response to Preoperative Chemoradiation Therapy in Rectal Cancer.

Authors:  Sun Gyo Lim; Young Bae Kim; Seung Yeop Oh
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

9.  Routine defunctioning stoma after chemoradiation and total mesorectal excision: a single-surgeon experience.

Authors:  Shao-Chieh Lin; Po-Chuan Chen; Chung-Ta Lee; Hong-Ming Tsai; Peng-Chan Lin; Helen H W Chen; Yuan-Hwa Wu; Bo-Wen Lin; Wen-Pin Su; Jenq-Chang Lee
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

10.  The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer.

Authors:  Yusuke Shimodaira; Kazuto Harada; Quan Lin; Jaffer A Ajani
Journal:  Ann Transl Med       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.